Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2003-12-09
2010-11-30
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252110, C514S252190, C514S253090, C514S254020, C514S254050, C514S254060, C514S254070, C544S371000, C544S121000, C544S238000, C544S295000, C544S357000, C544S364000, C544S366000, C544S367000, C544S370000
Reexamination Certificate
active
07842693
ABSTRACT:
Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
REFERENCES:
patent: 3362956 (1968-01-01), Archer
patent: 3478032 (1969-11-01), Arya
patent: 3491098 (1970-01-01), Archer
patent: 3723433 (1973-03-01), Ueno et al.
patent: 3950354 (1976-04-01), Wenzelburger et al.
patent: 3994890 (1976-11-01), Fujimura et al.
patent: 4166452 (1979-09-01), Generales, Jr.
patent: 4174393 (1979-11-01), Van Daalen et al.
patent: 4256108 (1981-03-01), Theeuwes
patent: 4265874 (1981-05-01), Bonsen et al.
patent: 4310429 (1982-01-01), Lai
patent: 4442102 (1984-04-01), Heinemann et al.
patent: 4547505 (1985-10-01), Oepen et al.
patent: 4559341 (1985-12-01), Petersen et al.
patent: 4562189 (1985-12-01), Tomcufcik et al.
patent: 4672063 (1987-06-01), Jasserand et al.
patent: 4772604 (1988-09-01), Van Wijngaarden et al.
patent: 4880809 (1989-11-01), Sugihara et al.
patent: 4997836 (1991-03-01), Sugihara et al.
patent: 5011928 (1991-04-01), Venero et al.
patent: 5177078 (1993-01-01), Ward et al.
patent: 5215989 (1993-06-01), Baldwin et al.
patent: 5227486 (1993-07-01), Merce-Vidal et al.
patent: 5292739 (1994-03-01), Merce-Vidal et al.
patent: 5346896 (1994-09-01), Ward et al.
patent: 5382586 (1995-01-01), Merce Vidal et al.
patent: 5464788 (1995-11-01), Bock et al.
patent: 5580985 (1996-12-01), Lee et al.
patent: 5607936 (1997-03-01), Chiang et al.
patent: 5646151 (1997-07-01), Kruse et al.
patent: 5681954 (1997-10-01), Yamamoto et al.
patent: 5719156 (1998-02-01), Shue et al.
patent: 5756504 (1998-05-01), Bock et al.
patent: 5760028 (1998-06-01), Jadhav et al.
patent: 5760225 (1998-06-01), Yuan
patent: 5780475 (1998-07-01), Baker et al.
patent: 5798359 (1998-08-01), Shue et al.
patent: 5968938 (1999-10-01), Williams et al.
patent: 6043246 (2000-03-01), Fukami et al.
patent: 6114334 (2000-09-01), Kerrigan et al.
patent: 6191159 (2001-02-01), Pinto
patent: 6207665 (2001-03-01), Bauman et al.
patent: 6288083 (2001-09-01), Luly et al.
patent: 6329385 (2001-12-01), Luly et al.
patent: 6372746 (2002-04-01), Corbera-Arjona et al.
patent: 6384035 (2002-05-01), Hutchings et al.
patent: 6451339 (2002-09-01), Patel et al.
patent: 6455544 (2002-09-01), Friedhoff et al.
patent: 6469041 (2002-10-01), Yuan
patent: 6492375 (2002-12-01), Snutch
patent: 6518273 (2003-02-01), Chapman et al.
patent: 6979686 (2005-12-01), Naraian et al.
patent: 7157464 (2007-01-01), Pennell et al.
patent: 2002/0022624 (2002-02-01), Dinnell et al.
patent: 2002/0040020 (2002-04-01), Bretenbucher et al.
patent: 2002/0045613 (2002-04-01), Pauls et al.
patent: 2002/0045749 (2002-04-01), Lai
patent: 2002/0049205 (2002-04-01), Li et al.
patent: 2002/0077321 (2002-06-01), Khanna et al.
patent: 2002/0107255 (2002-08-01), Bllumberg et al.
patent: 2002/0119961 (2002-08-01), Blumberg et al.
patent: 2003/0087917 (2003-05-01), Starck et al.
patent: 2003/0139425 (2003-07-01), Bauman et al.
patent: 2003/0149021 (2003-08-01), Li et al.
patent: 2004/0082571 (2004-04-01), Pennell et al.
patent: 2004/0162282 (2004-08-01), Pennell et al.
patent: 2005/0256130 (2005-11-01), Pennell et al.
patent: 2006/0122234 (2006-06-01), Archer et al.
patent: 2007/0010530 (2007-01-01), Beavers et al.
patent: 0 225 217 (1988-02-01), None
patent: 0 479 546 (1992-04-01), None
patent: 1 006 110 (2000-06-01), None
patent: WO 97/10219 (1997-03-01), None
patent: WO 97/44329 (1997-11-01), None
patent: WO 98/25617 (1998-06-01), None
patent: WO 98/39000 (1998-09-01), None
patent: WO 98/56771 (1998-12-01), None
patent: WO 99/07351 (1999-02-01), None
patent: WO 99/09984 (1999-03-01), None
patent: WO 99/25686 (1999-05-01), None
patent: WO 99/32468 (1999-05-01), None
patent: WO 99/37619 (1999-07-01), None
patent: WO 99/37651 (1999-07-01), None
patent: WO 00/31032 (2000-06-01), None
patent: WO 00/46195 (2000-08-01), None
patent: WO 00/46196 (2000-08-01), None
patent: WO 00/46197 (2000-08-01), None
patent: WO 00/46198 (2000-08-01), None
patent: WO 00/46199 (2000-08-01), None
patent: WO 00/47539 (2000-08-01), None
patent: WO 00/53600 (2000-09-01), None
patent: WO 00/69815 (2000-11-01), None
patent: WO 00/69820 (2000-11-01), None
patent: WO 00/69848 (2000-11-01), None
patent: WO 02/08221 (2002-01-01), None
patent: WO 02/14314 (2002-02-01), None
patent: WO 02/070523 (2002-09-01), None
patent: WO 03/008395 (2003-01-01), None
patent: WO 03/024450 (2003-03-01), None
patent: WO 03/051842 (2003-06-01), None
patent: 03/105853 (2003-12-01), None
patent: WO 2004/009550 (2004-01-01), None
patent: WO 2004/013130 (2004-02-01), None
patent: WO 2004/035556 (2004-04-01), None
CHEMCATS Database (Chemical Abstracting Service), Accession No. 2003:2855298, Jan. 1, 2004 for CAS Registry No. 492422-98-7.
CHEMCATS Database (Chemical Abstracting Service), Accession No. 2001:2759474, Oct. 20, 2003 for CAS Registry No. 351986-92-0.
Bebernitz et al. J. mMd. Chem. vol. 44, pp. 2601-2611 (2001).
Beilstein Database, Accession No. BRN 9229443 XP002254-63, Abstract for Vovk et al. Russ. J.Org.Chem. 36(12),pp. 1747-1752 (2001).
Anders, et al., A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J Clin Invest. (2002) 109(2):251-9.
Badran, M. et al., “Indazole derivatives (part III): synthesis of pyrazolo-[1,2-a]indazole-1,9-dione,[1,2,4]triazino[1,2-a]indazole-1,10-dione, 3-(Indazol-1-yl)propionic acid amides and hydrazides possessing potential biological activity”Alex. J. Pharm. Sci. (1999) 13(2):101-106.
Bendele, et al., Animal models of arthritis: relevance to human disease, Toxicologic Pathol. (1999) 27:134-142.
Berge, S.M., et al., Pharmaceutical Salts, Journal of Pharmaceutical Sciences (1977) 66:1-19.
Czarnocka-Janowicz, A. et al., “Synthesis and pharmacological activity of 5-substituted-s-triazole-3-thiols”Pharmazie(1991) 46:109-112.
Database Crossfire Beilstein ′Online! Beilstein Institut zur Forderung der Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession No. BRN 6982047 XP002254060 abstract & Varasi et al.,Farmaco Ed. Sci. (1987) 42(6):425-436.
Database Crossfire Beilstein ′Online! Beilstein Institut zur Forderung der Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession No. BRN 1159762 XP002254062 abstract & Zotta et al.,Farmacia(1977) 25:129-134.
Database Crossfire Beilstein ′Online! Beilstein Institut zur Forderung der Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession No. BRN 6000843 XP002254061 abstract & Toja et al.,Heterocycles(1987) 26(8):2129-2138.
Devries, M. et al., “On the edge: the physiological and pathophysiological role of chemokines during inflammatory and immunological responses”Sem. Immun. (1999) 11:95-104.
Fischer, F. et al., “Modulation of experimental autoimmune encephalomyelitis: effect of altered peptide ligand on chemokine and chemokine receptor expression”J. Neuroimmun. (2000) 110:195-208.
Foks, H. et al., “Synthesis of new 5-substituted 1,2,4-triazole-3-thione derivatives”Phosphorus, Sulfur and Silicon(2000) 164:67-81.
Gao, et al., Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection, J Clin Invest. (2000) 105(1):35-44.
Hayao, S. et al., “New antihypertensive aminoalkyltetrazoles”J. Med. Chem. (1967) 10:400-402.
HCAPLUS; Accession No. 1984:630511, Document No. 101:230511; Japanese Patent No. 59130890, issued Jul. 27, 1984; Abstract, 4 pages.
Hesselgesser, J. et al., “Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor”J. Biol. Chem. (1998) 273(25):15687-15692.
Izikson, L. et al., “Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine rec
Aggen James B.
Dairaghi Daniel Joseph
Martichonok Valeri V.
McMaster Brian E.
Pennell Andrew M. K.
Bernhardt Emily
ChemoCentryx, Inc.
Townsend and Townsend / and Crew LLP
LandOfFree
Substituted piperazines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted piperazines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted piperazines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4247701